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Abstract
Cholinergic neurons are widespread, and pharmacological modulation of acetylcholine receptors
affects numerous brain processes, but such modulation entails side effects due to limitations in
specificity for receptor type and target cell. As a result, causal roles of cholinergic neurons in
circuits have been unclear. We integrated optogenetics, freely moving mammalian behavior, in
vivo electrophysiology, and slice physiology to probe the cholinergic interneurons of the nucleus
accumbens by direct excitation or inhibition. Despite representing less than 1% of local neurons,
these cholinergic cells have dominant control roles, exerting powerful modulation of circuit
activity. Furthermore, these neurons could be activated by cocaine, and silencing this drug-
induced activity during cocaine exposure (despite the fact that the manipulation of the cholinergic
interneurons was not aversive by itself) blocked cocaine conditioning in freely moving mammals.
Acetylcholine is an important and widely studied neurotransmitter, which acts on a variety
of receptors and target cells (1–5). Pharmacological and genetic studies have elucidated the
complex and often opposing influences of the individual subtypes of muscarinic and
nicotinic acetylcholine receptors on numerous biological processes, but no study has yet
resolved the question of the causal role of cholinergic neurons themselves within a central
nervous system tissue (6–11). Addressing such a question would require a novel paradigm
for selective and temporally precise control (activation and inhibition) of cholinergic
neurons within living mammalian tissues, because previous investigations have resulted in
contradictory findings linked to challenges with specificity and temporal resolution. For
example, elegant in vivo pharmacological approaches have shown (12–14) that cholinergic
transmission in the nucleus accumbens (NAc) [a structure involved in natural reward-related
behaviors and responses to drugs such as cocaine (15–19)] is required for reward learning,
but novel studies of molecular ablation of cholinergic interneurons within the NAc instead
have reported enhanced reward learning (20). Cholinergic interneurons within the NAc are
particularly intriguing because they constitute less than 1% of the local neural population
(21), yet they project throughout the NAc and provide its only known cholinergic input (22).
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Relevant cholinergic receptors are expressed locally, and nicotinic and muscarinic
pharmacological agonists can exert complex influences on medium spiny neurons (MSNs,
which represent >95% of the local neuronal population and constitute the output of the NAc)
(23–25). However, the net effect (if any) of the cholinergic interneurons on any aspect of
NAc physiology or behavior is unknown.
We undertook an optogenetic approach to resolve this question by selectively driving or
blocking action potential firing in these cells. To express microbial opsin genes specifically
in cholinergic interneurons, we employed a transgenic mouse line expressing Cre-
recombinase under the choline acetyltransferase (ChAT) promoter (26). We stereotaxically
injected into the NAc (Fig. 1A) a Cre-inducible adeno-associated virus (AAV) vector
carrying the opsin gene fused in-frame with coding sequence for enhanced yellow
fluorescent protein (eYFP) (27, 28); the opsin gene encoded either the blue-light gated
cation channel channelrhodopsin-2 (ChR2) (29) or the yellow-light gated third-generation
chloride pump halorhodopsin (eNpHR3.0) (30). eYFP expression was specific to neurons
that expressed ChAT; moreover, the majority of neurons that expressed ChAT also
expressed eYFP (Fig. 1, B and C). Both opsins were expressed on the surface membranes of
ChAT neurons (Fig. 1D), and the targeted neurons responded to current injection in a
manner corresponding to previously established responses of cholinergic interneurons in the
dorsal striatum (Fig. 1E) (31). Both the resting membrane potential (Vm) and input resistance
(Rinput) were higher for ChAT neurons (YFP+ neurons) than for MSNs [identified as YFP−
neurons; table S1; P < 10−4 for VM and P = 0.004 for Rinput, two-tailed t test]. Finally, both
opsins were functional in ChATcells, as eNpHR3.0 drove large hyperpolarizations (Fig. 1F;
mean ± SEM: −83.8 ± 11.9 mV, n = 4) and ChR2 reliably drove spiking up to 20 to 30 Hz
(Fig. 1, G and H).
ChAT interneurons are thought to be tonically active in vivo (3 to 10 Hz) (32, 33), but it has
remained mysterious how (or even if) this slow activity in the sparse ChAT cells could be
causally involved in affecting local circuit activity or behavior. We used optogenetics to
address this question with a combination of slice electrophysiology, in vivo
electrophysiology, and freely moving behavior. First, we monitored postsynaptic currents in
MSNs (ChR2-eYFP non-expressing cells) in acute NAc slices during optogenetic
photostimulation of ChAT cells expressing ChR2-eYFP (Fig. 2A), targeted as in Fig. 1.
Stimulating ChAT neurons in this setting increased the frequency of γ-aminobutyric acid
type A (GABAA) receptor–mediated inhibitory postsynaptic currents (IPSCs) recorded in
MSNs (Fig. 2, B and C). Evoked inhibitory currents were generally synchronized to the light
pulse, with a modal latency of 6 ms (Fig. 2D), coupled with a smaller enhancement of
asynchronous IPSCs (fig. S1, A to C). Across all recorded cells, the mean frequency of
IPSCs observed in the MSNs increased by 525.8 ± 154.3% during light stimulation of the
ChAT neurons (n = 7; mean ± SEM, P = 0.01, paired t test), whereas the mean IPSC
amplitude was unaffected (P > 0.05, paired t test; n = 7, Fig. 2E). This effect was attenuated
by the nicotinic antagonist mecamylamine (fig. S3, n = 5, P < 0.05, paired t test).
We next asked if and how these changes in inhibitory current frequency would translate into
changes in MSN spiking in vivo. We recorded neural activity extracellularly with an optrode
in the NAc during optogenetic activation of the ChAT interneurons in vivo (Fig. 2F). At
sites where single units were not isolated, we observed neural population firing that tracked
the light stimulation at 10 Hz but not 100 Hz (fig. S1D), probably representing population
spiking across the sparse but synchronously activated ChAT cells in the neighborhood of the
electrode. In contrast to these population spikes, the isolated units in the NAc displayed a
markedly different response to the optogenetic photostimulation. In agreement with the
observed increase in IPSC frequency in MSNs in slices, we observed inhibition of
background firing during stimulation of the ChATcells in vivo (representative cell, Fig. 2G).
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Across the population, most significantly modulated sites showed a suppression of
background firing, although a few responded with an increase in firing (Fig. 2, H and I),
consistent with known recurrent inhibition among MSNs and corresponding release from
inhibition, during ChAT neuron drive, that had been previously exerted by the broader MSN
population.
We next explored the consequences of specifically inhibiting ChAT interneurons, employing
Cre-dependent eNpHR3.0 expression in vivo. In contrast to what was observed with ChAT
neuron excitation, firing of NAc neurons was typically increased in likely MSNs by
optogenetic inhibition of the ChAT cells (a representative cell is shown in Fig. 3A). Power
spectral analysis revealed a frequency peak in the firing pattern at ~4 Hz in these in vivo
recordings (Fig. 3B). Summary data are presented in Fig. 3C; across the population of
significantly modulated sites, most neurons were excited by the optogenetic inhibition of
ChAT neurons (n = 17). We were able to obtain a single-unit recording from a rare putative
ChAT interneuron, which was completely shut down by eNpHR3.0 (Fig. 3D) and displayed
the long action-potential duration characteristic of ChAT interneurons (22) (2.0 ms for this
cell, whereas spike durations for MSNs in our recordings ranged from 1.1 to 1.7 ms).
Summary data (Fig. 3E) show the dynamics of excitation and inhibition for all recorded
sites, illustrating the dominant pattern of excitation (firing increased by 130.5 ± 17.5% in
sites that were excited by light).
Finally, we sought to test if this potent NAc control mechanism was relevant to accumbens-
dependent reward behavior in freely moving mice. We first tested the effect of acutely
administered cocaine on activity of these identified ChAT neurons in acute NAc slices. In
ventro-medial NAc ChAT cells, cocaine tended to increase spontaneous firing
(representative ChAT neuron shown in Fig. 4, A and B). Summary data revealed that
cocaine increased firing rates from 0.60 ± 0.41 Hz to 1.74 ± 0.56 Hz at 10 min in ChAT
neurons (n = 7; P < 0.005, paired t test), whereas in the control group of cells receiving only
vehicle, firing rates decreased from 0.69 ± 0.24 Hz to 0.09 ± 0.09 Hz over the same time
period (n = 6; P < 0.05 comparing the two groups, two-tailed t test) (Fig. 4C).
We next used eNpHR3.0 to test for causal roles in either this cocaine-induced activity or
baseline activity of ChAT cells in the reward-related behavior of cocaine conditioned place
preference (CPP), in which animals learn to associate an environment with cocaine. After
injecting virus and implanting cannulae bilaterally (Fig. 4D) to silence ChAT neurons during
cocaine exposure (Fig. 4E), mice that expressed eNpHR3.0 in the ChAT cells exhibited
significantly less cocaine-induced CPP than did their control (Cre recombinase-negative)
littermates that had received the same virus, surgery, and light-delivery protocol [20 mg/kg
intraperitoneally(ip), Fig.4, F and G; n = 10 ChAT∷Cre+, n = 12 ChAT∷Cre− (left panel); P
< 0.01 for two-tailed t test; three cohorts; see also fig. S2A]. We observed no behavioral
effect of inhibiting the ChAT cells in the absence of cocaine, and ChAT neuron inhibition
by itself was not aversive, as conditioning with eNpHR3.0 alone did not affect place
preference (Fig. 4G, right panel; n = 9 ChAT∷Cre+, n = 7 ChAT∷Cre−; P > 0.05 for two-
tailed t test; three cohorts; fig. S2B; see also fig. S4A for cocaine dose-response curve).
Activation of the cells with ChR2 at 10 Hz was not sufficient to drive place preference by
itself or enhance cocaine place preference (10 and 20 mg/kg ip, fig. S4, B to D), with our
data from ChAT cell inhibition instead demonstrating necessity of these cells. Finally, in
control experiments, we found that ChAT neuron inhibition by itself had no effect on
mobility or anxiety in the open field (Fig. 4, H and J), and contextual- and auditory-cued
fear conditioning were not disrupted by inhibition of the ChAT cells (fig. S5).
Together, these data demonstrate that selectively inhibiting ChAT interneurons in the NAc
with high temporal precision has the overall effect of increasing MSN activity and blocking
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cocaine conditioning in freely moving mammals. These behavioral results do not support
conclusions arising from chronic ablation of the cholinergic interneurons (20); instead they
are more consistent with interpretations arising from faster but less cellularly targeted
pharmacological modulation in the NAc(12–14). Ablation of the cholinergic interneurons
might lead to indirect effects, such as a compensatory increase in dopamine in the NAc,
which, in turn, could enhance cocaine reward. In fact, a fundamental difference between
acute and chronic manipulations could explain clinically relevant apparent contradictions in
our understanding of the acetylcholine/dopamine balance in the brain. For example, an acute
increase in nicotine (presumably acting on cholinergic receptors) causes a corresponding
acute increase in dopamine (34), whereas chronic changes in dopamine or acetylcholine
levels can cause opposing changes in the levels of the other neuromodulators (35), as seen in
the dopamine depletion of Parkinson'sdisease(36).
Because cocaine increases dopamine levels in the NAc, the multiple classes of dopamine
receptors expressed on the various cell types within the NAc will give rise to substantial
complexity. Although the neural encoding of both cocaine and natural stimuli in the NAc is
heterogeneous (37), the predominant effect of appetitive stimuli may be to decrease activity
in the MSNs (inhibitory projection neurons), thereby gating directed behavior through
disinhibition of target brain regions. Consistent with this picture, a pause in NAc activity
(which we have found that ChAT neurons are well-suited to implement) may be required for
reward-related conditioning (38, 39); in contrast, the predominant effect of aversive stimuli
may be to increase MSN activity (40, 41). The fact that acute silencing of ChAT
interneurons disrupts drug-related learning without affecting conditioning in the absence of
drug suggests that control over this microcircuit could be used to selectively disrupt effects
of drugs of abuse without affecting appetitive or aversive responses in general, a possibility
that would be of substantial clinical benefit. Together, our results point to a powerful role for
these sparsely distributed neurons in controlling local circuit activity and implementing
behavioral conditioning in freely moving mammals.
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Specificity, membrane targeting, and functionality of ChR2 and eNpHR3.0 in ChAT inter-
neurons of the NAc. (A) Cre-dependentAAV[expressing either eNpHR3.0-eYFP or
ChR2(H134R)-eYFP] was injected into the medial portion of the NAc.(B) Confocal image
of an injected slice demonstrates colocalization of eYFP expression with the ChAT
antibody, costained with 4′,6′-diamidino-2-phenylindole (DAPI). (C) 91.3 ± 1.3% of
neurons that expressed YFP also stained for the ChAT antibody (n = 418); 93.5 ± 2.8% of
neurons that stained for the ChAT antibody also expressed YFP (n = 413). Error bars
indicate SEM. (D)High-magnification view reveals membrane localization of eNphR3.0-
eYFP (left) and ChR2-eYFP (right), costained with ChAT antibody. (E) Membrane potential
changes induced by current injection in a ChR2-eYFP-expressing ChAT neuron. VM = −48
mV. Current steps: −60, −20, +20 pA. (F) Membrane potential changes induced by 1 s of
580-nm light in an eNpHR3.0-eYFP-expressing ChAT neuron (peak hyperpolarization:
−103 mV). VM = −49 mV. (Inset) Population-averaged peak hyperpolarization (mean ±
SEM: −83.8 ± 11.9 mV; n =4). (G) Consecutive action potentials in a ChR2-eYFP-
expressing ChAT neuron evoked by a 470-nm pulse train (5 ms pulse width;10Hz).(H)
Average success probability for generating action potentials in ChR2-eYFP-expressing
ChAT neurons at different stimulation frequencies (n = 4; mean ± SEM; 470-nm pulse train,
5-ms pulse width).
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Optogenetic photoactivation of ChAT interneurons increases frequency of inhibitory
currents and suppresses MSN spiking. (A)ChAT neurons transduced with ChR2-eYFP were
activated with blue light (470 nm) in brain slices, and nearby MSNs (eYFP− cells) were
whole-cell patch-clamped. (B) (Left) Spontaneous synaptic currents were observed in an
MSN in a slice expressing ChR2-eYFP in ChAT neurons. (Middle) Synaptic currents
increased in frequency in response to 470-nm light pulses (5-ms pulse width; 10 Hz). (Right)
These currents were blocked by GABAA receptor antagonist SR-95531 (5 mM) and are thus
considered IPSCs. 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione
(NBQX) (5 mM) and (RS)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid (RS-
CPP) (5 μM) were present in all experiments. (C)Time course of IPSC frequencies for this
MSN, showing the effect of light pulses (blue dashed bars) and SR-95531 (black bar).
(D)Average percentage increase in IPSC frequency during the light-on periods (normalized
to that of light-off periods) as a function of time relative to light pulses (n = 6). The blue
dashed line indicates the onset of light pulses; error bars denote SEM. (E) Light pulses
increased the frequency of IPSCs by 525.8 ± 154.3% (n =6, P = 0.01, paired two-tailed t
test), whereas the average amplitudes of spontaneous IPSCs were changed by 21.3 ± 28.9%
(P >0.05). (F) An optrode (optical fiber attached to a tungsten electrode) was stereotaxically
positioned in vivo into a NAc that expressed ChR2-eYFP in ChAT cells. (G) (Top) Voltage
trace of an isolated unit that is inhibited by blue light stimulation. (Middle) Raster plot
displaying the response of the same unit to five repetitions of the light stimulation, with each
action potential represented by a dot. (Bottom) Average and SEM of the firing rate over time
for the same unit. (H) Fraction of sites that were inhibited versus excited by light
stimulation. (I) Population summary of the time course of response to light stimulation for
sites that were inhibited (left; n = 13 of 16) or excited (right; n =3 of 16)by light. Solid lines
represent average firing rate across sites as a function of time; each dot represents the
average firing rate of an individual site. All firing rates are normalized to the mean rate
before light stimulation. (F to I) Duration of photostimulation, 10 s; pulse duration, 5 ms;
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wavelength, 470 nm; frequency, 10 Hz. Epochs of light stimulation are represented by blue
dashed lines.
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Optogenetic photoinhibition of ChAT interneurons enhances MSN spiking in vivo. (A)
(Top) Voltage trace of an isolated unit (recorded from the NAc in vivo) that was excited by
optogenetic photoinhibition of the ChAT interneurons with eNpHR3.0. (Middle) Raster plot
displaying the response of the same unit to five repetitions of the light stimulation, with each
action potential represented by a dot. (Bottom) Average and SEM of the firing rate over time
for the same unit. (B) Wavelet analysis reveals power of spiking as a function of frequency
and time (average across five repetitions) for the same unit as in (A). (C) Fraction of sites
that were inhibited versus excited by light stimulation. (D) Sameas (A), for a unit that was
inhibited by light stimulation. (E) Population summary of the time course of response to
light stimulation for sites that were inhibited (left; n = 13 of 17) or excited (right; n = 4 of
17) by light. Solid lines represent the average firing rate across sites as a function of time;
each dot represents the average firing rate of an individual site. All firing rates are
normalized to the mean value before light stimulation. (A to E) Duration of
photostimulation, 15 s (constant illumination); wavelength, 560 nm. Epochs of light
stimulation are represented by yellow bars.
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ChAT interneurons can be activated by cocaine in slice and required for cocaine
conditioning in vivo. (A) The frequency of spontaneous action potentials in a ChAT neuron
increased 10 min after bath application of cocaine (5 μM). ACSF, artificial cerebrospinal
fluid. (B) Firing rate over time for this ChAT neuron. Horizontal gray bar, application of
cocaine; vertical dotted line, 10 min after cocaine application, the time point illustrated in
detail in (A) and (C). (C) Population data illustrating the cocaine-induced increase in firing
in ChAT neurons, comparing the baseline firing rate (averaged over the 2.5 min before
cocaine application) with the rate after cocaine infusion (averaged between 10 and 12.5 min
after onset of cocaine application; gray bars, cells receiving cocaine; white bars, control cells
receiving only ACSF; P < 0.005, paired two-tailed t test for cocaine-treated group before
versus after cocaine; P < 0.05 unpaired two-tailed t test comparing cocaine versus control
cells after cocaine or vehicle). (D) Schematic illustration of a bilateral cannula system with
double fibers inserted to illuminate the medial portion of the NAc. (Left inset) Endpoint of
cannula track for all mice used in (H). (Right inset) eYFP expression in NAc of a
ChAT∷Cre+ mouse injected with Cre-dependent eNpHR3.0-eYFP. (E) Conditioning
paradigm for cocaine CPP (H). Mice were conditioned with ip cocaine (20 mg/kg), along
with ChAT cell inhibition with eNpHR3.0 (wavelength: 590 nm). (F) Tracking data from
representative ChAT∷Cre+ and ChAT∷Cre− mice on the testing day after cocaine
conditioning (day 3). On the previous day (day 2), the mice had received cocaine and light
in one left chamber, whereas in the other they received saline. The ChAT∷Cre− mouse (but
not the ChAT∷Cre+ mouse) exhibited a preference for the conditioned chamber. (G) (Left)
Fold change in time in conditioned chamber during day 3 versus day 1 of cocaine CPP
(conditioning with cocaine and light). Comparison of ChAT∷Cre+ and ChAT∷Cre−
littermates; in both cases injected with Cre-dependent eNpHR3.0 (n = 10 ChAT∷Cre+, n =
12 ChAT∷Cre−; P < 0.01 for two-tailed t test; three cohorts). (Right) Fold change in time in
conditioned chamber during day 3 versus day 1 for conditioning with light alone (no
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cocaine; n = 9 ChAT∷Cre+, n = 7 ChAT∷Cre; P > 0.05 for two-tailed t test; three cohorts).
Error bars indicate SEM. n.s., not significant. (H) Velocity of virus-injected (Cre-dependent
eNpHR3.0) and photostimulated ChAT∷Cre+ and ChAT∷Cre− mice in the open field (n = 10
ChAT∷Cre+, n = 10 ChAT∷Cre−; P > 0.05 for two-tailed t test; three cohorts). (I) Same as
(H) for track length in open field (n = 10 ChAT∷Cre+, n = 10 ChAT∷Cre−; P > 0.05 for two-
tailed t test; three cohorts). (J) Same as (H) for time in center of open field (n = 10
ChAT∷Cre+, n = 10 ChAT∷Cre; P > 0.05 for two-tailed t test; three cohorts). (A to J) *P <
0.05; **P < 0.01; ***P < 0.005.
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